Free tool
FAERS Monitor: Libtayo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761097 or its brand name (Libtayo, Cemiplimab-Rwlc). Reports on generic versions are filed under their own applications.
Reports
2,083
Serious
1,728
83% of reports
Hospitalization
608
Death reported
438
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death176
- disease progression155
- off label use107
- fatigue88
- rash86
- dyspnoea65
- pyrexia64
- pruritus53
- interstitial lung disease50
- myocarditis50
- asthenia47
- drug ineffective47
- diarrhoea46
- nausea45
- pneumonia41
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 7 |
| 2019 | 138 |
| 2020 | 105 |
| 2021 | 204 |
| 2022 | 292 |
| 2023 | 258 |
| 2024 | 345 |
| 2025 | 435 |
| 2026 | 299 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,076 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myocarditisSignal | 50 | 44.2 | 33.6 | 2,062 |
| disease progressionSignal | 155 | 13.2 | 11.4 | 1,750 |
| interstitial lung diseaseSignal | 50 | 10.4 | 7.9 | 418 |
| deathSignal | 176 | 2.1 | 1.8 | 99 |
| rash | 86 | 2.0 | 1.6 | 42 |
| pyrexia | 64 | 1.9 | 1.5 | 25 |
| pruritus | 53 | 1.4 | 1.1 | 6 |
| pneumonia | 41 | 1.3 | 0.9 | 2 |
| asthenia | 47 | 1.3 | 1.0 | 2 |
| off label use | 107 | 1.2 | 1.0 | 5 |
| dyspnoea | 65 | 1.2 | 0.9 | 1 |
| fatigue | 88 | 1.1 | 0.9 | 1 |
| diarrhoea | 46 | 0.7 | 0.5 | 5 |
| nausea | 45 | 0.6 | 0.4 | 14 |
| drug ineffective | 47 | 0.4 | 0.3 | 56 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.